scholarly journals Isthmin is a novel vascular permeability inducer that functions through cell-surface GRP78-mediated Src activation

2015 ◽  
Vol 107 (1) ◽  
pp. 131-142 ◽  
Author(s):  
Shruthi Venugopal ◽  
Mo Chen ◽  
Wupeng Liao ◽  
Shi Yin Er ◽  
Wai-Shiu Fred Wong ◽  
...  

Author(s):  
Yuan-Li Tsai ◽  
Amy S. Lee


2015 ◽  
Vol 1 (10) ◽  
pp. e1500821 ◽  
Author(s):  
Hong-Bo Pang ◽  
Gary B. Braun ◽  
Erkki Ruoslahti

Cell-penetrating peptides (CPPs) have been widely used to deliver nanomaterials and other types of macromolecules into mammalian cells for therapeutic and diagnostic use. Cationic CPPs that bind to heparan sulfate (HS) proteoglycans on the cell surface induce potent endocytosis; however, the role of other surface receptors in this process is unclear. We describe the convergence of an HS-dependent pathway with the C-end rule (CendR) mechanism that enables peptide ligation with neuropilin-1 (NRP1), a cell surface receptor known to be involved in angiogenesis and vascular permeability. NRP1 binds peptides carrying a positive residue at the carboxyl terminus, a feature that is compatible with cationic CPPs, either intact or after proteolytic processing. We used CPP and CendR peptides, as well as HS- and NRP1-binding motifs from semaphorins, to explore the commonalities and differences of the HS and NRP1 pathways. We show that the CendR-NRP1 interaction determines the ability of CPPs to induce vascular permeability. We also show at the ultrastructural level, using a novel cell entry synchronization method, that both the HS and NRP1 pathways can initiate a macropinocytosis-like process and visualize these CPP-cargo complexes going through various endosomal compartments. Our results provide new insights into how CPPs exploit multiple surface receptor pathways for intracellular delivery.



2016 ◽  
Author(s):  
Vaishali Kapoor ◽  
David Dadey ◽  
Kim Nguyen ◽  
Hua Li ◽  
Buck Rogers ◽  
...  


2019 ◽  
Vol 294 (38) ◽  
pp. 13939-13952 ◽  
Author(s):  
Udhayakumar Gopal ◽  
Yvonne Mowery ◽  
Kenneth Young ◽  
Salvatore Vincent Pizzo


2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 31-31
Author(s):  
Ali Al-Hashimi ◽  
Richard Austin ◽  
Bobby Shayegan

31 Background: Prostate cancer (PC) is characterized by increased prothrombotic state due to enhanced tissue factor (TF) expression/procoagulant activity (PCA). We and others observed that GRP78, a molecular chaperone, is expressed on the surface of PC cells where it functions as a signaling receptor to promote cell proliferation and survival. Further, exposure of GRP78 on the surface of PC cells stimulates the production of anti-GRP78 autoantibodies in PC patients. We have reported that binding of these autoantibodies to cell surface GRP78 enhances TF PCA. We hypothesize that this autoantibody/cell surface GRP78 complex interaction increases PC progression and that disruption of this complex would represent a viable target for the treatment of advanced PC. Methods: Wild type, TF knockdown DU145 cells, and NOD/SCID mouse model system was used to investigate the effect of anti-GRP78 autoantibodies on tumor growth. Protein expression was determined using western blotting and qRT-PCR. TF activity was determined using the TF PCA continuous assay. Blood samples from patients diagnosed with PC were obtained from the Ontario Tumour Bank and St. Joseph’s Hamilton. Results: Pre-prostatectomy patients demonstrated high levels of anti-GRP78 autoantibodies (60-100µg/ml) vs. healthy individuals (5-10µg/ml). These titers were significantly reduced 24-weeks post prostatectomy. We show here that anti-GRP78 autoantibodies upregulate TF and its PCA through a mechanism involving depletion of ER Ca2+ stores. This very effect on ER Ca2+ stores also caused activation of the unfolded protein response, a pro-survival cellular pathway. Furthermore, these autoantibodies were shown to accelerate tumor growth in a NOD/SCID mouse model. Finally, heparin and low molecular weight heparin were shown to interfere with the binding of these antibodies to cancer cells and prevent PC cell activation. Conclusions: We have identified the function of an agent in patients' blood, anti-GRP78 autoantibodies, that correlate with PC stage in patients and increase TF PCA and promote PC progression in mice. The effect of this autoantibody can be reversed using heparin, thus, this acts as a new potential therapeutic target for PC.



2017 ◽  
Vol 24 (9) ◽  
pp. 1518-1529 ◽  
Author(s):  
Morgane Louessard ◽  
Isabelle Bardou ◽  
Eloïse Lemarchand ◽  
Audrey M Thiebaut ◽  
Jérôme Parcq ◽  
...  


2013 ◽  
Vol 45 (5) ◽  
pp. 987-994 ◽  
Author(s):  
Zongwei Li ◽  
Lichao Zhang ◽  
Yarui Zhao ◽  
Hanqing Li ◽  
Hong Xiao ◽  
...  






Sign in / Sign up

Export Citation Format

Share Document